Drug intelligence / Profile preview

MAQ-002

Development stage: Preclinical
Lead developer: MabQuest Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MAQ-002 is a preclinical-stage bispecific antibody developed by MabQuest Therapeutics for the treatment of various cancers. It is designed to target Programmed Cell Death Protein 1 (PD-1) along with an additional undisclosed target to potentially provide enhanced therapeutic efficacy over conventional anti-PD-1 monoclonal antibodies. The program is part of MabQuest's pipeline focused on next-generation immuno-oncology therapies that aim to overcome resistance mechanisms in the tumor microenvironment.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on MAQ-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAQ-002.

Explore the full profile